U.S. flag

An official website of the United States government

NM_000251.3(MSH2):c.942+2_942+11del AND Hereditary cancer-predisposing syndrome

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Jan 26, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002443407.2

Allele description [Variation Report for NM_000251.3(MSH2):c.942+2_942+11del]

NM_000251.3(MSH2):c.942+2_942+11del

Gene:
MSH2:mutS homolog 2 [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
2p21
Genomic location:
Preferred name:
NM_000251.3(MSH2):c.942+2_942+11del
HGVS:
  • NC_000002.12:g.47414420_47414429del
  • NG_007110.2:g.16297_16306del
  • NM_000251.3:c.942+2_942+11delMANE SELECT
  • NM_001258281.1:c.744+2_744+11del
  • LRG_218:g.16297_16306del
  • NC_000002.11:g.47641559_47641568del
  • NM_000251.1:c.942+2_942+11del10
Molecular consequence:
  • NM_000251.3:c.942+2_942+11del - splice donor variant - [Sequence Ontology: SO:0001575]
  • NM_001258281.1:c.744+2_744+11del - splice donor variant - [Sequence Ontology: SO:0001575]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002682921Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Pathogenic
(Jan 26, 2021)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Ambry Genetics, SCV002682921.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The c.942+2_942+11del10 pathogenic mutation, located in intron 5 of the MSH2 gene, results from a deletion of 10 nucleotides within intron 5 of the MSH2 gene. Due to the polyA region from c.942+3 to c.942+29, this deletion only affects the c.942+2 position of the canonical donor site. Alterations that disrupt the canonical splice site are expected to result in aberrant splicing. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. The resulting transcript is predicted to be in-frame and is not expected to trigger nonsense-mediated mRNA decay; however, direct evidence is unavailable. The exact functional effect of the missing amino acids is unknown; however, the impacted region is critical for protein function (Ambry internal data). Two alterations impacting the same donor site (c.942+2T>C and c.942+2T>A) have been detected in individuals whose Lynch-related tumors demonstrated high microsatellite instability, loss of MSH2/MSH6 expression on immunohistochemistry and family histories were consistent with Lynch syndrome (Ambry internal data; de Lellis L at al. PLoS ONE 2013;8(11):e81194; Castillejo MI et al. eJIFCC Volume 27 no 1; February 2016). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 1, 2024